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Background: The first rate-limiting step for improving outcomes of psychosis through 
preventive interventions in people at clinical high risk for psychosis (CHR-P) is the ability to 
accurately detect individuals who are at risk for the development of this disorder. Currently, 
this detection power is sub-optimal.
Methods: This is a conceptual and nonsystematic review of the literature, focusing on 
the work conducted by leading research teams in the field. The results will be structured 
in the following sections: understanding the CHR-P assessment, validity of the CHR-P as 
a universal risk state for psychosis, and improving the detection of at-risk individuals in 
secondary mental health care, in primary care, and in the community.
Results: CHR-P instruments can provide adequate prognostic accuracy for the 
prediction of psychosis provided that they are employed in samples who have undergone 
risk enrichment during recruitment. This substantially limits their detection power in real-
world settings. Furthermore, there is initial evidence that not all cases of psychosis onset 
are preceded by a CHR-P stage. A transdiagnostic individualized risk calculator could 
be used to automatically screen secondary mental health care medical notes to detect 
those at risk of psychosis and refer them to standard CHR-P assessment. Similar risk 
estimation tools for use in primary care are under development and promise to boost 
the detection of patients at risk in this setting. To improve the detection of young people 
who may be at risk of psychosis in the community, it is necessary to adopt digital and/or 
sequential screening approaches. These solutions are based on recent scientific evidence 
and have potential for implementation internationally.
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INTRODUCTION
Preventive strategies in young people at clinical high risk for psychosis 
[CHR-P (1)] can ameliorate the high personal, familial, societal, 
and clinical burden of psychotic disorders (2). CHR-P criteria, 
which include the ultra-high-risk state [e.g., at-risk mental state (3) 
or other psychosis-risk syndromes (4)] and/or basic symptoms (5), 
are detected by specialized clinical services (6) through established 
psychometric assessment tools (7), in the context of a clinical 
interview (8). These tools are internationally validated (7) and 
assess whether the individual is meeting at least one of the three 
ultra-high-risk subgroups: attenuated psychotic symptoms (~85% 
of cases), genetic risk and deterioration syndrome (5% of cases), 
or brief and limited intermittent psychotic symptoms (BLIPS, 10% 
of cases) (3, 9) subgroup. Individuals at CHR-P recruited from 
help-seeking clinical samples have a 20% probability of developing 
emerging psychotic disorders (but not other nonpsychotic disorders 
(10, 11)) over 2 years (12). This risk increases to 50% at 2 years for 
the BLIPS subgroup and to 89% at 5 years for the subset of BLIPS 
patients who present with seriously disorganizing and dangerous 
features (13). Overall, the real-world potential impact of the CHR-P 
paradigm for improving the outcomes of psychotic disorders will 
be determined by the successful and stepped integration of three 
key components (Figure 1): (i) efficient detection of individuals 
at risk for psychosis, (ii) accurate prognosis of outcomes, and (iii) 
effective preventive treatment. 
As illustrated in Figure 1, the first rate-limiting step for 
improving outcomes of psychosis through the CHR-P paradigm 
is the real-world ability to detect most individuals who are at 
risk for psychosis and will later develop it. Efficient detection 
of individuals at CHR-P has been a relatively neglected area of 
research in spite of the fact that inefficient detection impedes 
subsequent efforts. In fact, even the most accurate prognostic 
model and effective preventive treatment would exert a 
modest impact if they are only applied to a small proportion 
of those who later develop psychosis. The first challenge is 
that, to date, there has been an assumption that the CHR-P 
stage represents the prototypical prepsychotic stage for most 
individuals who will later go on to develop psychosis. However, 
in a thematic issue in Schizophrenia Bulletin titled “Dissecting 
the diagnostic pluripotentiality of the ultra high risk state for 
psychosis,” (Volume 44, Issue 2, 2018) (15–18), a meta-analysis 
demonstrated that the onset of psychosis may also occur via 
previously identified nonpsychotic clinical risk syndromes (17). 
Separately, independent research groups have reported that 
first-episode psychosis (FEP) cases may occur without a prior 
identifiable period of subthreshold psychotic symptoms (19, 
20). The second challenge is that even assuming that the CHR-P 
concept would be sufficient to detect the majority of individuals 
at risk, its real-world penetrance is undetermined. Emerging 
evidence suggests that current detection strategies for identifying 
individuals at CHR-P are highly inefficient. These strategies 
Conclusions: The best strategy to improve the detection of patients at risk for 
psychosis is to implement a clinical research program that integrates different but 
complementary detection approaches across community, primary, and secondary 
care. These solutions are based on recent scientific advancements in the development 
of risk estimation tools and e-health approaches and have the potential to be applied 
across different clinical settings. 
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FIGURE 1 | Core clinical components for effective prevention of psychosis. The first rate-limiting step for improving outcomes of psychosis through preventive 
approaches is the ability to accurately detect individuals at risk for psychosis. Adapted from (14), Creative Commons Attribution License (CC BY).
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are largely based on referrals to specialized CHR-P clinics (6), 
made on suspicion of psychosis risk. Only 5% of individuals who 
had presented with a first onset of nonorganic psychosis to the 
local NHS Trust had been detected by one local CHR-P service 
(21). Since the service had been fully established in the same 
Trust, there is a clear need to improve the detection of at-risk 
cases (22). To our best knowledge, there are no other original 
studies published to date reporting on the detection power of 
the CHR-P paradigm that could further validate or replicate these 
findings. Inefficient detection has important clinical implications. 
For example, although the NHS England’s Access and Waiting 
Times-Standard for Early Intervention in psychosis (23) requires 
that CHR-P are detected nationwide and treated within 2 weeks, 
current detection strategies are inefficient. A first viable alternative 
may be to intensify the outreach campaigns currently adopted by 
CHR-P clinics. Converging evidence has demonstrated that such 
an approach conflicts with the intrinsic psychometric limitations 
of the CHR-P interviews, producing a diluted transition risk (24, 
25) and unreliable prognostic accuracy. Another option may 
be to implement front-line youth mental health services such as 
the Headspace initiative (other youth mental health services are 
available worldwide; for a recent review, see (26)). Because of their 
one-stop-shop nature (26–28), youth-friendly services are expected 
to improve the attraction and detection of potential individuals 
who may be at risk of psychosis. Unfortunately, there are no 
original data reporting on the efficacy of detecting individuals at 
CHR-P through youth mental health services. Rough estimates 
indicate only a modest improvement of detection when adopting 
broad youth mental health services, with 12% of individuals 
with FEP being detected at the time of their CHR-P phase (29) 
(Figure 2). Therefore, at present, between 88% (Headspace model) 
and 95% [Outreach and Support in South London (OASIS) model] 
of individuals who will later develop psychosis remain undetected 
at the time of their CHR-P stage (see Figure 2).
In order to extend the preventive benefits of the CHR-P 
paradigm, more sophisticated and innovative approaches are 
urgently needed (30).
The current manuscript will review this issue in a 
comprehensive conceptual analysis of the current challenges 
and propose evidence-based ways for overcoming them. The 
detection program presented here integrates three separate 
approaches targeting different populations: secondary mental 
health care, primary care, and the community. The overarching 
methodology of this detection program leverages the recent 
advancements brought by clinical risk estimation tools (31) and 
digital approaches. 
METHOD
This is a conceptual but nonsystematic review of the literature, 
which focuses on the areas of work conducted by our research 
teams. As such, the information included here largely reflects our 
conceptual opinion regarding the best path forward an improved 
detection of CHR-P individuals. We will first review the 
conceptual foundation of the CHR-P assessments, a necessary 
step to grasp their intrinsic limitations. Following this analysis, 
we will appraise the conceptual validity of the CHR-P stage as a 
universal and prototypical risk state for psychosis. Then, we will 
propose empirical ways for improving the detection of CHR-P 
FIGURE 2 | Detection power of at-risk patients who will later develop a first-episode of psychosis under different preventive programs: OASIS and headspace. 
CHR-P: Clinical High Risk for Psychosis. New figure.
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individuals. The results are structured in the following sections: 
understanding the CHR-P assessment, validity of the CHR-P 
as universal risk state for psychosis, improving the detection of 
at-risk individuals in secondary mental health care, improving 
the detection of psychosis in primary care, and improving the 
detection of psychosis in the community. 
RESULTS
Understanding The CHR-P Assessment
CHR-P cohorts are not representative of the local general population 
because recruitment is affected by sampling biases. To exemplify 
this, in the general population of South London, the cumulative 
3-year incidence of psychotic disorders is 0.43% (32) (Figure 3). 
The recruitment of individuals for undergoing a 
CHR-P assessment is primarily based on unstructured and 
heterogeneous selection and sampling strategies based on the 
clinicians’ suspicion of psychosis risk (33) and help-seeking 
behavior (37). These recruitment processes determine the 
extent to which individuals at CHR-P would accumulate 
several risk factors for psychosis (Figure 3) (22, 38); in turn, the 
accumulation of risk factors determines the level of functional 
impairment (39, 40) and associated attenuated psychotic 
symptoms (Figure 4) (8). Broadly speaking, individuals are 
generally recruited from secondary mental health care, primary 
care, or the community and represent different populations on 
the basis of clinical and functional characteristics. The current 
manuscript will be structured around strategies to detect these 
three different populations.
FIGURE 3 | Sampling procedure for individuals at clinical high risk for psychosis (CHR-P) (33). Idiosyncratic recruitment strategies that are characterized by 
heterogeneous sampling biases (convenience and judgmental sampling) result in accumulation of various risk factors for psychosis and differential level of 
enrichment of psychosis risk. The risk before the CHR-P assessment is completed is termed pretest risk or prevalence. The risk after the CHR-P assessment is 
completed is termed posttest risk (positive if CHR-P criteria are met and negative if CHR-P criteria are not met). The figure is based on the data reported in (32, 34, 
35). CAARMS: Comprehensive Assessment of At-Risk Mental States; SIPS: Structured Interviews for Psychosis-Risk Syndromes; DSM-5-APS: Diagnostic and 
Statistical Manual, 5th Edition, Attenuated Psychosis Syndrome. Adapted from (36), Creative Commons Attribution License (CC BY).
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The type of recruitment strategies adopted will influence 
the level of risk of psychosis for these individuals. This level of 
risk is also defined as pretest risk (or prevalence) because it is 
ascertained in the whole group of people undergoing a CHR-P 
assessment before the results of the assessment itself are known 
(41). The relative increase in enrichment in this pretest risk, 
which is acquired through the recruitment step, is substantial 
(i.e., from 0.43 to 15%, ~35-fold higher). This pretest risk 
enrichment is also highly heterogeneous across different sites 
because it is unstandardized and not controlled for (32, 33, 42). 
For example, it is highest if recruitment targets secondary mental 
health care, intermediate if recruitment targets primary care, and 
lowest if it targets the nonhelp-seeking community (33). Clinical 
help-seeking samples who undergo pretest risk enrichment 
during the recruitment phase are then tested by specialized clinics 
(6). These clinics administer a comprehensive psychometric 
CHR-P assessment in the context of a clinical interview (43). 
Overall, a meta-analysis has confirmed that the prognostic 
accuracy of this CHR-P assessment is considered to be good 
(i.e., area under the curve at 38 months = 0.90, 95%CI 0.87–0.93) 
(7) and comparable to that of similar prognostic measurements 
employed in other areas of medicine (7). As illustrated in Figure 
3, when help-seeking individuals presenting to a CHR-P service 
with a 15% pretest risk at 3 years are assessed (tested), those who 
meet CHR-P criteria will have a 26% risk of developing psychosis 
at 3 years (1.7-fold increase) and those who do not meet the 
FIGURE 4 | Putative model of the onset and progression of psychosis in relation to nonpurely genetic risk factors and developmental processes affected by the 
disorder. Sociodemographic and parental and perinatal risk factors have been implicated during the preclinical phase, usually observed from the birth to infancy, 
childhood, and early adolescence. Additional later factors occurring during later adolescence and early adulthood can trigger the onset of attenuated psychotic 
symptoms, functional impairment, and help-seeking behavior, which constitute the CHR-P stage. The diagnosis of psychosis, which operationally corresponds to 
FEP, is usually made during the adolescence or early adulthood, with a peak at 15–35 years of age (38). Once diagnosed, psychosis usually follows a fluctuating 
course punctuated by acute exacerbation of psychotic crises superimposed upon a background of poorly controlled negative, neurocognitive, and social cognitive 
symptoms. The pink boxes represent the risk factors for psychosis as identified by a recent umbrella review (38). There is no assumption that these risk factors are of 
causal nature or that they are independent from each other. Furthermore, certain risk factors may actually represent outcomes of earlier risk factors. Figure based on 
the data reported in (22). CHR-P: clinical high risk for psychosis; FEP: first-episode psychosis. Adapted from (36), Creative Commons Attribution License (CC BY).
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CHR-P criteria will have a 1.56% risk of developing psychosis at 
3 years (10-fold decrease). However, these numbers indicate that 
the CHR-P tools can accurately predict the onset of psychosis 
(but not of other nonpsychotic mental disorders (11)) in samples 
who have been enriched in their risk for developing psychosis 
(7). If these tools are used to screen the general population, the 
pretest risk would be low, and even meeting CHR-P criteria 
would be associated with only a 5% risk of developing psychosis 
at ~3 years (24, 25). In other words, the overall accuracy of the 
CHR-P assessment is driven by a high power to rule out a state 
of risk for psychosis in samples that are risk enriched, but only a 
modest capacity to rule in a state of risk for psychosis (7). 
These arguments clearly indicate that the CHR-P paradigm has 
the greatest utility when used to detect help-seeking populations 
that are accessing specialized clinical services (6). Intensifying 
outreach campaigns targeting the community would reduce 
the pretest risk and, in turn, dilute the prognostic accuracy of 
the CHR-P approach, thereby impeding effective preventive 
interventions. These considerations will be used to inform the 
detection approach proposed in the following sections.
Validity Of The CHR-P Paradigm As 
Universal Risk State For Psychosis
Most contemporary research on transitions from an at-risk state 
to FEP has been conducted with help-seeking individuals who 
are identified as being in CHR-P states. While this is undoubtedly 
valuable in its own right, there is emerging evidence that 
identification and intervention at the point of CHR-P currently 
detect only a small proportion of patients who eventually develop 
FEP (21). These findings dovetail with the sampling biases that 
characterize CHR-P studies (44) and, from a public health 
perspective, lead to the question of what proportion of FEP cases 
were in fact preceded by a CHR-P state. 
The contemporary meta-analytical literature has revealed 
that reported risk of conversion from a CHR-P stage to FEP 
(29% at 2 years in 2012 (45)) has decreased internationally in 
recent years (20% at 2 years in 2016 (12)). However, this is not 
universal; for example, in South London, the risk of psychosis 
has remained stable over two decades (42). There is evidence 
suggesting that the decline in transition is linked to a change in 
recruitment strategies (42). Whatever the impact of recruitment 
strategies on the risk for psychosis onset, there is no evidence 
that the declining conversion rates in the most recent years 
have been matched by a similar change in the incidence of FEP 
(46–48). This implies that FEP cases passing through a CHR-P 
state are not being identified by existing CHR-P research and 
clinical infrastructures and/or that some individuals developed 
FEP without experiencing an identified preonset CHR-P state 
(19, 20). Congruent with this, it has been speculated that, in 
community samples, those who develop FEP may vary in their 
clinical backgrounds and outcomes to a greater extent than in 
those presenting to academic institutions (49). 
First, the possibility that nonpsychotic risk syndromes could 
precede the first onset of psychosis has been demonstrated for 
some time and was recently summarized in a meta-analysis (17). 
Within prospective studies (n = 4, sample = 1,051), the pooled 
incidence of new psychotic disorders across these clinical risk 
syndromes was of 12.9 per 1,000 person-years. Within the same 
prospective studies, the incidence of common (nonpsychotic) 
disorders (n = 3, sample = 538) was of 43.5 per 1,000 person-years 
(95% CI: 30.9, 61.3) (17). The study concluded that nonpsychotic 
risk states may give rise to psychotic disorders, albeit at lower 
rates than in the CHR-P group (Figure 5).
Second, although the CHR-P state is not associated with an 
increased risk of developing new or emerging nonpsychotic 
mental disorders (10), at follow-up, many of them have other 
mental illnesses that were already present at baseline, in particular, 
depressive, anxiety, or substance-use disorders (50, 51). Since 
individuals at CHR-P often develop nonpsychotic disorders, it is also 
plausible that some individuals experiencing FEP had developed 
this without a prior CHR-P syndrome (i.e., without any past 
presence of subthreshold psychotic symptoms). Indeed, recently 
two retrospective cohort studies using different instruments each 
found a reasonably large subgroup of patients with FEP for whom 
there was no evidence of meeting prior CHR-P criteria for any 
identifiable length of time (19, 20). This cumulates to ~30% of the 
cases experiencing FEP (Figure 6).
Subsequent work has explored the longitudinal evolution of 
patients with FEP who did versus did not experience a preonset 
CHR-P stage. While there were no clinical or functional 
differences at baseline (entry to early intervention services) 
between patients with FEP with and without prior CHR-P states, 
such differences emerged after 1 year of early intervention services: 
those with preonset symptoms consistent with a CHR-P state 
had poorer psychotic symptom outcomes and global functioning 
(52). Furthermore, there is more frequent nonadherence to 
antipsychotic medication in the preonset/CHR-P state group 
(although without corresponding differences in insight) (53). Since 
this work involved retrospective assessments, it is possible that 
FEP cases without evidence of a preonset CHR-P phase exhibited 
a recall bias and that the true prevalence of symptoms consistent 
with a CHR-P state was substantially higher than measured. 
Nonetheless, it indicates that the CHR-P stage may not be the 
unique, universal clinical stage preceding the onset of psychosis. 
Therefore, to detect more individuals at risk for psychosis, it may 
be necessary to go beyond the CHR-P operationalization and to 
adopt a broader transdiagnostic approach (54) that cuts across 
psychopathological dimensions. For example, there is evidence 
that a first episode of schizophrenia-like psychosis can occur 
from depressive or bipolar disorders (22). This concept has 
informed the development of transdiagnostic risk calculators for 
this population, as detailed in the following section.
Improving The Detection Of Individuals At 
Risk In Secondary Mental Health Care
As noted in the introduction, most individuals accessing the 
mental health trust in South London who later developed psychosis 
were not detected at the time of their potential CHR-P stage. This 
happened in spite of the long-standing implementation of the local 
specialized CHR-P clinic, the OASIS (6) over the previous two 
decades, which was conducting an extensive outreach campaign. 
For example, the clinic uses a youth-friendly website to promote 
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FIGURE 5 | Three-year risk of developing psychosis in different samples at risk. The incidence of psychotic disorders in the general population is significantly 
influenced by geographical, ethnical, environmental, and the diagnostic criteria of psychosis. However, it can be approximated at 0.43% at 3 years. Help-seeking 
samples that undergo a CHR-P assessment have a 15% risk of psychosis at 3 years. After the assessment is completed, those who do not meet the CHR-P criteria 
have a 1.54% risk of psychosis at 3 years, while those who meet the CHR-P criteria have a 26% risk at 3 years. Clinical risk syndromes other than psychosis have a 
3.9% risk of psychosis at 3 years. New figure using data from (17, 36). CHR-P: Clinical High Risk for Psychosis.
FIGURE 6 | Proportion of patients with first episode psychosis (FEP) who presented with subthreshold psychotic symptoms (consistent with a theoretical CHR-P stage) or 
not before developing FEP, retrospective analysis of medical records. CHR-P: clinical high risk for psychosis; FEP: first episode psychosis. New figure using data from (19).
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help-seeking behavior and referrals (https://www.meandmymind.
nhs.uk). As noted above, it is possible to estimate that up to 
two-thirds of these FEP cases developed their first onset of the 
disorder through a CHR-P like stage. As such, the majority of the 
individuals who developed psychosis would have been detected 
had these individuals been referred to the local CHR-P (OASIS) 
clinic. Importantly, all these young people were already under 
the care of a mental health team. As such, they clearly represent 
a window of missed opportunities for improving the detection of 
individuals at risk. Targeting this population would, therefore, be 
the most obvious first step towards improved detection of at-risk 
individuals. Within individuals in secondary mental health care, 
there is an incidence of psychosis of 3% at 6 years, which is higher 
than the risk of psychosis of 0.62 at 6 years in the local general 
population (22). The solution to this problem is not simple. One 
way would be to screen all patients accessing the local mental 
health trust using the existing CHR-P instruments. This option is 
logistically and financially unsustainable. The alternative may be 
to intensify outreach campaigns. However, as noted above (33), 
these are highly inefficient and dilute the pretest risk of psychosis 
and, consequently, the prognostic meaningfulness of meeting 
CHR-P criteria per se. 
To overcome this substantial challenge, a clinically based, 
individualized, transdiagnostic risk calculator has been 
developed, which includes features that help improve the 
detection of individuals at risk for psychosis. First, this risk 
calculator has been externally validated twice: in South London 
and Maudsley NHS Trust and in Camden and Islington NHS 
Trust (14, 22, 55). External validation of prognostic models in 
psychiatry is infrequent (31). Second, this calculator could be 
applied to mental health trusts where there are no established 
CHR-P programs to detect patients at risk as in the Camden and 
Islington Mental Health Trust. Third, this calculator is low cost 
and simple to run because it uses 10th revision of the International 
Statistical Classification of Diseases and Related Health Problems 
index diagnoses (which is considered transdiagnostic because it 
allows several diagnostic spectra (54)), age, gender, age by gender, 
and ethnicity as key predictors, which have been selected on the 
basis of a priori clinical knowledge (31, 56). A recent version of 
the refined calculator that includes an advanced age predictor 
is also available (57). Fourth, the calculator is deliberately 
transdiagnostic and includes those meeting the CHR-P state as 
well as patients who might develop psychosis outside it, meaning 
that it can potentially detect the subgroup of patients who will 
go on to develop psychosis outside the CHR-P state. Fifth, the 
calculator can be automatized because it leverages electronic 
health records to screen secondary mental health care trusts. 
Therefore, it has great potential to be applied at scale, which is 
an essential prerequisite to improve the detection of patients 
at risk for psychosis. Sixth, the calculator is individualized, in 
that it provides prognostic outcomes at the individual subject 
level. This is a substantial advantage compared with the current 
CHR-P strategy, which is limited by group-level prediction, at 
risk or not at risk, with few exceptions such as the risk calculator 
by Cannon et al (58, 59). However, Cannon's risk calculator (58, 
59) should be used only in individuals already meeting CHR-P 
criteria to predict their clinical outcomes; as such, Cannon's 
algorithm is not suited to improve the detection of individuals at 
risk in primary, secondary care, or in the community. Seventh, the 
transdiagnostic calculator can be further improved by the addition 
of more sophisticated predictors or by the stepped combination of 
sequential testing, which can improve prognostic accuracy in the 
CHR-P field (60). 
This transdiagnostic risk calculator has been implemented 
in clinical care as part of an ongoing study funded by a Medical 
Research Council grant. Because external validation studies are 
rare, to our best knowledge, there are no other implementation 
studies of risk calculators for CHR-P patients. The proliferation 
of risk models in the CHR-P field as well as in psychiatry has 
occurred largely without appropriate attention to implementation 
challenges, resulting in many models that have little or no clinical 
impact (61). In fact, many more risk prediction models are 
published than are externally validated, and only a few of these 
are then implemented in the NHS (31). To achieve successful 
implementation, which is the true measure of a prediction 
model’s utility, we carefully considered potential implementation 
challenges from the beginning of the model building process. 
Because our aim was to improve the detection of individuals 
at risk of psychosis, it was necessary to screen a large NHS 
Trust at scale. To achieve this goal, we selected predictors that 
were already collected by clinicians as part of their clinical 
routine. Furthermore, the requirement of simple variables for 
implementation increases the number of datasets that could be 
used for the external validation of existing models, a current gap 
in the implementation of risk prediction models in psychiatry. 
The implementation study protocol for this transdiagnostic risk 
calculator has just been published (14). As indicated in Figure 7, 
this pilot study comprises of two subsequent phases: an in vitro 
phase of 1 month and an in vivo phase of 11 months.
The in vitro phase does not involve patients or clinicians, 
and it aims at developing and integrating the transdiagnostic 
risk calculator in the local electronic health register (primary 
outcome). The in vivo phase aims at addressing the clinicians’ 
adherence to the recommendations made by the transdiagnostic 
risk calculator (primary outcome) and other secondary feasibility 
parameters that are necessary to estimate the resources needed 
for its implementation. This pilot study is also the first to address 
the regulatory constraints that surround the automatic screening 
of electronic health-care records to detect patients at risk for 
psychosis [for a review, see (62)].
The study will be completed soon, and the results are expected 
over the next year. Should this study be successful, it will be 
followed by an effectiveness trial to test the real-world clinical 
and economic benefits of using this approach over standard care 
to detect patients at risk of psychosis in secondary mental health 
care. The complementary task would be to develop, validate, and 
implement risk calculators for the detection of patients at risk of 
psychosis in primary care, as highlighted in the following section.
Improving The Detection Of Individuals At 
Risk In Primary Care
In the UK, most people with psychosis enter specialist secondary 
care via referral from their primary care physician (63), and there 
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is some evidence that a shorter duration of untreated psychosis 
is associated with more primary care visits before diagnosis date 
(64). Primary care clinicians are therefore a vital part of the 
care pathway for people with psychosis, and it is consequently 
important that primary care clinicians can recognize a psychosis 
prodrome to expedite referral to specialist services for early 
treatment. Royal College of General Practitioners guidelines (65) 
stress the importance of detecting early signs and refer to some 
of the more common ones. There is evidence that the accuracy 
of psychosis diagnoses recorded on primary care electronic 
records is valid (66, 67), but there is also evidence that primary 
care physicians underidentify the more insidious symptoms (68). 
This is problematic because prodromal symptoms are frequently 
nonspecific and so may presage other health problems. In 
addition, most primary care physicians see very few new cases of 
psychosis per year and have little opportunity to increase personal 
experience in this area. There is also evidence (69) that there are 
barriers to referral for primary care when referring to specialist 
mental health services like CHR-P services. Therefore, there is a 
clear need for an accurate prognostic tool based in primary care. In 
line with the research program detailed above, it may be possible 
to use candidate predictors identified using clinical knowledge to 
develop and validate a prediction model based on primary care 
consultation data for nonpsychotic symptoms stored in electronic 
databases. Earlier studies (70) investigated the phases preceding 
psychosis, using a help-seeking general population sample from 
primary care consultation data collected before a diagnosis of 
psychosis and therefore unbiased by the presence of disorder. The 
sample used had a much larger number of cases (n = 11,690) than 
previous prospective studies. This method had the advantage of 
recording consultation events prospectively and should more 
accurately describe prodromal development. It was found that 
specific early behaviors and symptoms were strongly associated 
with a later diagnosis of psychosis, such as attention deficit 
hyperactivity-disorder-like problems, bizarre behavior, blunted 
affect, depressive-like problems, role functioning problems, social 
isolation, mania, obsessive–compulsive disorder-like problems, 
disordered personal hygiene, sleep disturbance, and suicidal 
behavior (including self-harm). The behaviors were cannabis 
use and cigarette smoking. The positive prognostic value of these 
behaviors and symptoms varied strongly with age and gender. 
There was also evidence of a pattern in consultation frequency 
per month for some of the prodromal behaviors and symptoms 
up to 5 years before diagnosis and evidence that people who 
are later diagnosed with psychosis are more frequent users of 
primary care services than those who do not develop psychosis. 
These findings can then be used to define candidate predictors 
for the development and validation of a psychosis detection and 
prediction model that can be used in primary care. 
This research program is still ongoing, and the key 
methodological steps are summarized below. For the 
development and internal validation, we will conduct a 
population-based retrospective cohort study with a follow-up 
of ≥8 years. The Clinical Practice Research Datalink Gold (CPRD 
(71)) model will be used as a training dataset. CPRD Gold is a 
computerized database of anonymized longitudinal UK PC 
FIGURE 7 | Potential clinical use of the individualized, clinically based, transdiagnostic risk calculator in secondary mental health care. For any new patient 
accessing the local NHS Trust (South London and Maudsley, UK), clinicians will enter the predictors on the electronic case register, as part of their clinical routine. 
The calculator, embedded in the local electronic health record, would then use the predictors to estimate the individual risk of developing psychosis over time. 
This information would then be shared with clinicians through automated alerts, inform their decision making, and promote appropriate referrals to the local early 
detection clinic (OASIS). From (55), Creative Commons Attribution License (CC BY).
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records, which covers approximately 22 million patients who are 
representative of the general UK population regarding age, sex, 
and ethnicity (72). Validation studies (73) report that the quality 
and completeness of data are high. To ensure that the recording 
of outcomes is complete, the CPRD Gold dataset will be linked 
to the Hospital Episode Statistics (HES) database (74), which 
records secondary health-care events in the UK. All patients 
within CPRD without a coded diagnosis of a psychotic disorder 
before 2010, but who consult for any mental health problem (a 
diagnosis or symptoms) from January 1, 2010 until the date of 
most recent general practitioner (GP) practice data download. 
Each patient will be regarded as at risk of a psychosis diagnosis 
from the date of the first consultation for a mental health problem 
of any nature. The end date will be the earliest date out of either 
the date on which HES records confirm a diagnosis of psychosis, 
or the date of data download, or the date the individual leaves 
the general practice or dies, or the practice ceases to provide data 
for CPRD.
The candidate predictors identified from our previous 
work (70) are described above. The primary outcome is any 
coded diagnosis of a psychotic disorder from HES records. We 
estimate that a CPRD dataset of the records of 300,000 people 
will contain at least 695 psychosis diagnoses, which exceeds 
the recommended event-per-variable ratio for risk prediction 
models (31). We will use robust multivariable and modern 
estimation methods employing shrinkage (75) (including 
LASSO) for variable selection, to guard against overfitting, along 
with a clinical judgement. Model performance will be assessed 
with calibration and discrimination, using well-established 
statistical performance measures (76). Time-varying predictors 
such as consultations per month will be incorporated within a 
Cox model. Internal model validation will quantify the model’s 
validity and the quality of predictors. 
External validation will be conducted in the CPRD Aurum 
database linked to HES. GP practices included in CPRD Aurum 
only use EMIS primary care software for recording consultation 
data. Consequently, there is little or no overlap between the 
training and validation datasets. In internal model validation, 
calculations will be performed using bootstrap or cross-
validation. In external validation, model performance measures 
will be calculated, and we will also report whether the prediction 
model is clinically useful using decision curve analysis to 
quantify the net benefit leading to an optimal decision threshold. 
Weighting of false versus true positive will be defined using 
clinician opinion (from the study team) and relevant literature 
(77). The final result will be a risk prediction algorithm—P risk 
(Figure 8).
Should this study be successful, it will lead to the next 
stage, which will be further external validation and pilot 
implementation of the P-risk algorithm in a live primary care 
setting. Following successful implementation, we would seek 
to test the effectiveness, cost effectiveness, and acceptability of 
P-risk using a randomized controlled trial design that would 
randomize a pop-up of the P-risk algorithm result to GPs and 
compare referral rates with GPs who do not receive the pop-up 
(see Figure 8).
Improving The Detection Of Individuals At 
Risk In The Community
An obvious avenue for extending the detection of emerging 
psychosis to the community is through electronic mental health 
approaches. A recent study by Birnbaum et al. (78) surveyed 
the use of internet and social media resources among patients 
with FEP. The majority of patients actively sought information 
regarding mental health issues online and had positive attitudes 
toward online interventions. Accordingly, these data provide 
support for the idea that wider identification of psychosis may 
benefit from digital detection strategies (79). This possibility was 
tested as part of the Youth-Mental Risk and Resilience Study (80), 
a cross-sectional study to identify neurobiological mechanisms 
and predictors of psychosis risk. Specifically, the study 
implemented an online-screening tool (http://www.your-study.
org.uk), which consists of a web-based questionnaire (81) that 
utilizes the 16-item version of the Prodromal Questionnaire (PQ-
16) (82) and a 9-items of perceptual and cognitive aberrations 
for the assessment of basic symptoms. Such an approach is 
essential to minimize the caveats discussed above. While it is 
not recommended to directly screen the general population 
through CHR-P assessment tools, this can become viable if the 
samples have undergone some previous risk enrichment before. 
Using the PQ-16 ahead of the CHR-P assessment tool fulfills 
these requirements. In line with this approach, participants were 
invited to the study website via email invitations, posters, and 
flyers to take part in a study on mental health problems (81). 
It is estimated that a population of 150,000–200,000 students 
were contacted. Cut-off criteria for further clinical assessments 
were 6 or more positively endorsed items on the PQ-16 based 
on previous data, suggesting a correct classification of CHR-P 
criteria based on Comprehensive Assessment of At-Risk Mental 
States (CAARMS) interviews with high sensitivity and specificity 
(82). For the perceptual and cognitive aberrations, a cut-off score 
of 3 or more positively endorsed items was selected (Figure 9).
Three thousand five hundred participants completed the 
questionnaire online over a 4-year period. Our previous analysis 
(81) had shown that ~50% participants fulfilled the PQ-16 cut-off 
criteria, while ~70% met criteria for the perceptual and cognitive 
aberrations. Approximately 20% of participants who met online 
cut-off criteria and were contacted attended clinical assessments 
to establish CHR-P criteria based on the positive scale of the 
CAARMS (3) as well as through items of the Schizophrenia 
Proneness Instrument (adult version). Approximately one-
third of participants who met online cut-off criteria and who 
were interviewed met CHR-P criteria. Importantly, a subset of 
individuals (~5%) were also diagnosed with FEP and a substantial 
number of CHR-P participants had not received any intervention 
prior to the study. Receiver operating characteristic curve 
analysis revealed good to moderate sensitivity and specificity for 
predicting symptoms consistent with a CHR-P status based on 
online results for both CAARMS and Schizophrenia Proneness 
Instrument criteria (adult version) (sensitivity/specificity: PQ-16 = 
82%/46%; perceptual and cognitive aberrations = 94%/12%) 
(81). To examine the possibility of improving the specificity of 
the online screening tool, we implemented a machine-learning 
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approach that selected all 25 items from both the PQ-16 and the 
perceptual and cognitive aberrations in addition to demographical 
variables. Selection of a subset of 10 items from both PQ-16 and 
perceptual and cognitive aberrations that included familial risk 
lead to an improved specificity of 57% while only marginally 
affecting sensitivity (81%). 
These data provide the first evidence for the feasibility of using 
a digital detection tool to identify emerging psychosis in the 
community. However, several refinements are needed to improve 
this approach, in particular in regard to the specificity/sensitivity 
of the screener. This can be achieved, for example, by adding 
known risk factors for the development of psychotic disorders 
(21, 55) that can be efficiently integrated into a web- or app-based 
screening. Some members of our team are currently working 
on this line as part of a recently funded Wellcome Trust grant. 
Specifically, the online assessment will be complemented by the 
sequential use of the recently developed Psychosis Polyrisk Score 
(PPS, Figure 10). The use of the PPS can be particularly suited 
to detect those individuals who may be at risk of developing 
psychosis outside the CHR-P stage, as indicated above.
Sequential Risk Assessment
The PPS leverages recent findings indicating that risk enrichment 
in CHR-P samples is accounted for by the accumulation of 
nongenetic factors such as parental and sociodemographic risk 
factors, perinatal risk factors, later risk factors, and antecedents 
(22). Examples of these risk factors are illustrated in Figure 
10. The PPS additionally incorporates new meta-analytical 
evidence implicating specific risk factors that predict the onset 
of psychosis within CHR-P samples (83). The concurrent 
assessment of several demographic and environmental risk 
factors for psychosis may appear logistically unviable in clinical 
practice. However, it would be facilitated by a sequential testing 
FIGURE 8 | P-risk psychosis risk prediction algorithm operating on primary care data systems. New figure.
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procedure (60). For instance, all demographic and parental risk/
protective factors, as well as some environmental (urbanicity, 
winter/spring season of birth) and later risk factors (adult life 
events, tobacco use, cannabis use, childhood trauma, traffic) can 
be self-administered or automatically extracted from electronic 
medical records or from geolocating applications that capitalize 
on recent e-health advancements (79). For the individuals whose 
predicted polyrisk of psychosis is over a certain threshold, a 
clinical comprehensive PPS assessment can be performed in a 
sequential fashion (60). Such an assessment may involve more 
accurate testing to collect the remaining risk factors: blood 
sampling to assess the exposure to infective agents and to 
estimate the polygenic risk, consulting obstetric records, or by 
interviewing the patients’ relatives and clinical interviews. Such 
an approach would additionally allow incorporating a dynamic 
assessment framework, which may better reflect the fluctuating 
course of the disorder. In line with these arguments, the 
e-detection tool that will be developed by this program could also 
incorporate behavioral data obtained through mobile phones, 
which could add important dimensions to the characterization 
of cognitive and behavioral deficits of participants at CHR-P. 
There is consistent evidence that cognitive functions, such as 
processing speed, are a core dysfunction of emerging psychosis 
(84), which could be assessed through digital phenotyping 
(85). In this context, there is also data evidence that speech 
analysis can be used to identify emerging psychosis that could 
be potentially an additional domain for a digital phenotyping 
approach (86, 87).
Digital detection of emerging psychosis in the community 
also faces several challenges; the most important is the significant 
prevalence of subthreshold psychotic experiences in the general 
population (49, 88). There is a significant phenomenological and 
clinical difference between subthreshold psychotic symptoms that 
are self-reported by youths in the general populations as opposed 
to the symptoms disclosed by youths who are accessing CHR-P 
services and undergoing a clinical interview (for details, see (8)). 
As noted above (33), these differences are likely to be associated 
with different level of pretest risk enrichment and, as such, with 
differential prognostic outcomes. Accordingly, future studies are 
needed to understand the ethical implications and establish the 
long-term outcomes of CHR-P populations recruited from the 
community through the use of prescreening e-health methods. 
Nonetheless, while these are important challenges to overcome, 
in the modern digital world, it is likely that e-health approaches 
such as the one presented here will have an increasing role to 
play in the future for the detection of emerging psychosis. This 
could be particularly true if these approaches are combined with 
complementary strategies targeting secondary and primary care.
FIGURE 9 | e-Health strategy to improve the detection of individuals at CHR-P in the community. CAARMS: Comprehensive Assessment of At-Risk Mental States; 
CHR-P: clinical high risk for psychosis; FEP: first episode psychosis; PCA: Questionnaire of Perceptual and Cognitive Aberrations; PQ-16: 16-item version of the 
Prodromal Questionnaire; SPI-A: Schizophrenia Proneness Instrument. New figure.
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CONCLUSIONS
CHR-P instruments can provide reliable prognostic outcomes when 
they are employed in samples that have undergone risk enrichment 
during their recruitment. However, this enrichment substantially 
limits their detection power. Furthermore, there is evidence that 
psychosis onset may partially occur without a prior CHR-P stage and 
that nonpsychotic clinical risk states can precede FEP. To overcome 
these caveats, it is necessary to implement a clinical research 
program that integrates different but complementary detection 
approaches. A transdiagnostic individualized risk calculator could 
be used to automatically screen secondary mental health care to 
detect those at risk of psychosis and refer them to standard CHR-P 
assessment. Similar risk estimation tools for use in primary care are 
under development and promise to boost the detection of patients 
at risk in this setting. To improve the detection of young people 
who may be at risk of psychosis in the community, it is necessary to 
adopt e-health and sequential screening approaches that have been 
developed and are under refinement. These solutions are based on 
recent scientific evidence and can be potentially implemented into 
different contexts. Future research will test the cost effectiveness of 
these strategies, compared with current standards.
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FIGURE 10 | Putative Psychosis Polyrisk Score (PPS) assessment for the detection of at-risk individuals and the prediction of psychosis. Risk or protective factors 
that have been selected through umbrella reviews (38) are diluted during the preclinical stages but may accumulate as the individual progresses across different 
stages, until they trigger signs or symptoms and functional impairment that are associated with help-seeking behavior and access to mental health care. In the later 
stages, specific aggregations of risk and protective factors may be associated with specific clinical outcomes. Adapted from (36), Creative Commons Attribution 
License (CC BY).
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